For the quarter ending 2025-09-30, GLSI has $3,806,978 in assets. $1,622,001 in debts. $3,806,978 in cash and cash equivalents.
| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Acquired patents, net | - | 0 | ||
| Cash | 3,806,978 | 3,125,101 | ||
| Total assets | 3,806,978 | 3,125,101 | ||
| Unreimbursed expenses related party-Related Party | - | 82,852 | ||
| Deferred compensation related party-Related Party | - | 306,281 | ||
| Accounts payable & accrued interest | 1,108,886 | 1,296,476 | ||
| Deferred compensation related party | 306,281 | - | ||
| Unreimbursed expenses related party | 206,834 | - | ||
| Total current liabilities | 1,622,001 | 1,685,609 | ||
| Total liabilities | 1,622,001 | 1,685,609 | ||
| Common stock, 0.001 par value 100,000,000 shares authorized 13,794,577 and 13,152,729 shares issued and outstanding as of september 30, 2025 and december 31, 2024, respectively | 13,795 | 13,473 | ||
| Additional paid-in capital | 79,760,045 | 74,863,037 | ||
| Accumulated deficit | -77,588,863 | -73,437,018 | ||
| Total stockholders equity | 2,184,977 | 1,439,492 | ||
| Total liabilities and stockholders equity | 3,806,978 | 3,125,101 | ||
Greenwich LifeSciences, Inc. (GLSI)
Greenwich LifeSciences, Inc. (GLSI)